Clinical Scorecard: Phosphaturic Mesenchymal Tumours in the Sinonasal Region and Skull Base: A Case Series with Comprehensive Review

At a Glance

Key Highlights

• PMTs are rare in the sinonasal region and skull base, often leading to diagnostic challenges.
• Persistent hypophosphataemia is a vital diagnostic indicator.
• PET imaging showing somatostatin receptor positivity is a key diagnostic tool.
• All patients underwent surgical resection, with postoperative serum phosphorus levels normalizing within 4–10 days.
• Four out of five patients experienced diagnostic delays, with misdiagnoses including nasal polyps.

Guideline-Based Recommendations

Diagnosis

• Utilize PET imaging for diagnosis, particularly for somatostatin receptor expression.
• Monitor serum phosphorus levels for diagnostic confirmation.

Management

• Surgical resection is the primary treatment for PMTs.

Monitoring & Follow-up

• Postoperative monitoring of serum phosphorus levels to evaluate cure and recurrence.

Risks

• High rates of missed and misdiagnosis due to atypical clinical manifestations and tumour obscurity.

Patient & Prescribing Data

Five patients aged 28 to 67 years with confirmed sinonasal/skull base PMTs.

All patients underwent endoscopic surgery; one patient experienced recurrence after 2 years.

Clinical Best Practices

• Consider PMTs in differential diagnoses for patients with unexplained hypophosphataemia and bone pain.
• Employ comprehensive imaging techniques, including CT, MRI, and PET, for accurate diagnosis.

Related Resources & Content